Compare Banco Santander SA (SAN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Tango Therapeutics Inc. — how do they compare? Banco Santander SA trades at $13.38 (market cap $196.48B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Banco Santander SA is far larger — about 52.4× Tango Therapeutics Inc.'s market cap, and Banco Santander SA pays a 2.14% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Tango Therapeutics Inc. for 0 Days on average.
| SAN | TNGX | |
|---|---|---|
Market Cap | $196.48B | $3.75B |
Volume | 9,811,951 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $15.05 | $32.90 |
52-Week Low | $9.65 | $7.50 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $362.68B | $2.77B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.41, down 0.52% on the day, with a bearish technical signal from moving averages and a mixed earnings history including a Q1 2026 beat. The company maintains strong profitability with a 26.25% net income margin and a 16.07% ROE, supported by record profits highlighted in recent earnings calls. Recent developments include the completion of the Webster acquisition, expanding its U.S. presence, and a dividend payment scheduled for November 2026.
The outlook is cautiously optimistic with analyst consensus at 'Moderate Buy' (64% buy ratings), but risks include declining cash flows from operations and rising debt-to-asset ratios. Revenue growth is projected to reach $61.9B in 2026, though net cash flow turned negative in 2024-2025, signaling potential liquidity pressures. Investors should weigh strong profitability against financial leverage and integration risks from acquisitions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
